ReviewJournal of clinical medicine2022
Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Integrated network pharmacology and experimental investigation of the potential therapeutic effect of β-sitosterol in systemic lupus erythematosus.Inflammopharmacology · 2026Article
- Advances in the treatment of systemic lupus erythematosus.Nature reviews. Drug discovery · 2025Review
- Prediction of Systemic Lupus Erythematosus Exacerbation in Patients with Clinical and Subclinical Musculoskeletal Inflammation.Journal of clinical medicine · 2025Article
- Ultrasound clusters of joint inflammation in systemic lupus erythematosus: a cross-sectional study.Rheumatology international · 2025Article
- Clinical spectrum of rhupus syndrome: a series of eight cases.Rheumatology international · 2025Article
- Arthritis Mutilans: A Devastating Manifestation of Psoriatic Disease Without Dactylitis in a 61-Year-Old Patient.Cureus · 2025Article
- Rethinking arthritis: exploring its types and emerging management strategies.Inflammopharmacology · 2025Review
- A Rare Case of Cold Antibody-Mediated Autoimmune Haemolytic Anaemia in Early Systemic Lupus Erythematosus.Cureus · 2025Article
- Uncovering shared genetic features between inflammatory bowel disease and systemic lupus erythematosus.Scientific reports · 2025Article
- Prediction of Lupus Classification Criteria via Generative AI Medical Record Profiling.Biotech (Basel (Switzerland)) · 2025Article
- Dual seropositive nonerosive lupus arthritis: rhupus or not?Advances in rheumatology (London, England) · 2025Article
- Validation and optimization of classification criteria for childhood-onset systemic lupus erythematosus in a multi-center Chinese cohort.Frontiers in immunology · 2025Article
- Musculoskeletal manifestations in childhood-onset systemic lupus erythematosus: an in-depth exploration.Italian journal of pediatrics · 2024Article
- Article
- Examining the clinical and radiological landscape of rhupus: navigating the challenges in disease classification.Rheumatology international · 2024Review
- Joint surgery rates in lupus: a long-term cohort study.Lupus science & medicine · 2024Article
- Anorexia Nervosa in Juvenile Systemic Lupus Erythematosus (SLE): A Causality Dilemma.Children (Basel, Switzerland) · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Musculoskeletal involvement is one of the most common manifestations of systemic lupus erythematosus (SLE), with a negative impact on both quality of life and overall prognosis. SLE arthritis can be classified into three different subtypes, with different prevalence and characteristic biomarkers and MRI findings. Identifying the pathogenetic mechanisms underlying musculoskeletal manifestations' development is crucial to develop therapeutic strategies to suppress synovial inflammation, prevent erosions and deformities, and improve SLE patients' quality of life. Hence, here we discuss the main pathogenetic mechanisms and therapeutic approaches of musculoskeletal manifestations of SLE from the 2022 International GISEA/OEG Symposium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.